{"entity":{"id":"nct07335497","kind":"trial","name":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of CR-001 in advanced solid tumours, run by Crescent Biopharma, Inc., now recruiting.","summary":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07335497 by Crescent Biopharma, Inc., with 290 participants planned, started 2026-02-17 and due to reach its primary completion in 2029-02. Interventions recorded: CR-001.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07335497","url":"https://clinicaltrials.gov/study/NCT07335497"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07335497","phase":"1/2","setting":"A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","sponsor":"Crescent Biopharma, Inc.","enrolled":290,"outcomes":[]},"route":"/trials/nct07335497/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}